Page 4 - Bio Media Contact News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

- As previously announced, the primary endpoint was met with a highly statistically significant p-value - The placebo and acoramidis time-to-first event Kaplan-Meier curves for a composite of.

United statesVikram baliSteering committeeUniversity of south carolinaGlobenewswire incBridgebio pharma incEuropean society of cardiology congressExchange commissionDrug administrationSecurities exchangeAmerican heart associationNew drug applicationBio pharmaHeart associationScientific sessionsCardiology congress

BridgeBio Pharma Presents Additional Clinical Outcomes Data

- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related.

United statesVikram baliSecurities exchangeUniversity of south carolinaSteering committeeEuropean society of cardiology congressBridgebio pharma incBio pharma incDrug administrationExchange commissionAmerican heart associationWin ratioHazard ratioNew drug applicationBio pharmaScientific sessions

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study

- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant

United statesVikram baliAmerican heart associationExchange commissionBio pharma incDrug administrationEuropean society of cardiology congressSteering committeeBridgebio pharma incSecurities exchangeUniversity of south carolinaWin ratioHazard ratioNew drug applicationBio pharmaScientific sessions

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesVikram baliUniversity of south carolinaSecurities exchangeAmerican heart associationBio pharma incEuropean society of cardiology congressBridgebio pharma incExchange commissionDrug administrationSteering committeeWin ratioHazard ratioNew drug applicationBridgebio pharmaScientific sessions

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesBio cardiorenalVikram baliJonathan foxUniversity of south carolinaUs social security administrationAmerican heart associationDrug administrationExchange commissionSteering committeeBio pharma incEuropean society of cardiology congressHuman servicesSecurities exchangeBridgebio pharma incUs department of health